JP2015519333A - 神経疾患の治療のための組成物および方法 - Google Patents
神経疾患の治療のための組成物および方法 Download PDFInfo
- Publication number
- JP2015519333A JP2015519333A JP2015510892A JP2015510892A JP2015519333A JP 2015519333 A JP2015519333 A JP 2015519333A JP 2015510892 A JP2015510892 A JP 2015510892A JP 2015510892 A JP2015510892 A JP 2015510892A JP 2015519333 A JP2015519333 A JP 2015519333A
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- compound
- carboxamide
- composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COc1ccc(*)cc1 Chemical compound COc1ccc(*)cc1 0.000 description 4
- SKPWGBMKZNVXFF-UHFFFAOYSA-N CC(NCCOC(C)=O)=O Chemical compound CC(NCCOC(C)=O)=O SKPWGBMKZNVXFF-UHFFFAOYSA-N 0.000 description 2
- KIQLLHYPNCPLAJ-UHFFFAOYSA-N CNCCSCCNC Chemical compound CNCCSCCNC KIQLLHYPNCPLAJ-UHFFFAOYSA-N 0.000 description 2
- YEJSPQZHMWGIGP-UHFFFAOYSA-N COC(CCC(C(OC)=O)N)=O Chemical compound COC(CCC(C(OC)=O)N)=O YEJSPQZHMWGIGP-UHFFFAOYSA-N 0.000 description 2
- MJDTYNAFJVLFAP-UHFFFAOYSA-N CC(C)NCCSCCNC Chemical compound CC(C)NCCSCCNC MJDTYNAFJVLFAP-UHFFFAOYSA-N 0.000 description 1
- PMSSGBHWXUPKOP-BYPYZUCNSA-N CC([C@H](CS)N)=O Chemical compound CC([C@H](CS)N)=O PMSSGBHWXUPKOP-BYPYZUCNSA-N 0.000 description 1
- GSVDZENISSRBGR-LURJTMIESA-N CC([C@H](CS)NC(C)=O)=O Chemical compound CC([C@H](CS)NC(C)=O)=O GSVDZENISSRBGR-LURJTMIESA-N 0.000 description 1
- XMOLEHZEMRNQDS-NSHDSACASA-N CC([C@H](Cc(c1c2)c[nH]c1ccc2O)N)=O Chemical compound CC([C@H](Cc(c1c2)c[nH]c1ccc2O)N)=O XMOLEHZEMRNQDS-NSHDSACASA-N 0.000 description 1
- QQCSLLQLKRTTHN-UHFFFAOYSA-N CC(c(cccc1)c1OC(c1ccccc1O)=O)=O Chemical compound CC(c(cccc1)c1OC(c1ccccc1O)=O)=O QQCSLLQLKRTTHN-UHFFFAOYSA-N 0.000 description 1
- UFZNVUYYBIBOMK-UHFFFAOYSA-N CCNCCN(C)CCNC Chemical compound CCNCCN(C)CCNC UFZNVUYYBIBOMK-UHFFFAOYSA-N 0.000 description 1
- XXXJRCKYLBXNRX-GUBZILKMSA-N CNC(CCCC[C@@H]([C@H](C1)N2)SC[C@H]1NC2=O)=O Chemical compound CNC(CCCC[C@@H]([C@H](C1)N2)SC[C@H]1NC2=O)=O XXXJRCKYLBXNRX-GUBZILKMSA-N 0.000 description 1
- AOKCDAVWJLOAHG-UHFFFAOYSA-N CNCCCC(O)=O Chemical compound CNCCCC(O)=O AOKCDAVWJLOAHG-UHFFFAOYSA-N 0.000 description 1
- KVQGGLZHHFGHPU-UHFFFAOYSA-N COC(CCCN)=O Chemical compound COC(CCCN)=O KVQGGLZHHFGHPU-UHFFFAOYSA-N 0.000 description 1
- YQMCELIPRYYKHT-SNVBAGLBSA-N C[C@]1(CCCCC(C)=O)SSCC1 Chemical compound C[C@]1(CCCCC(C)=O)SSCC1 YQMCELIPRYYKHT-SNVBAGLBSA-N 0.000 description 1
- IUXNWFUQIHHJRP-UHFFFAOYSA-N Oc1ccccc1C(S)=O Chemical compound Oc1ccccc1C(S)=O IUXNWFUQIHHJRP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
Abstract
Description
eは、独立して、1,2または6であり;c及びdはそれぞれ独立して、H、 D、−OH 、−OD、C1− C6アルキル、 −NH 2または−COCH 3である。
eは、独立して、1,2または6であり;c及びdはそれぞれ独立して、H 、D 、 −OH 、−OD 、C1− C6アルキル、−NH 2または−COCH 3である。
スキーム2:
Claims (20)
- 請求項1または2の化合物を含む医薬組成物、および薬学的に許容される担体。
- 請求項2に記載の化合物および薬学的に許容される担体を含む医薬組成物。
- 医薬組成物は経口投与によって必要とする患者に投与する有効量の基礎となる病因を治療するために処方される、請求項3に記載の医薬組成物、遅延放出または持続放出、経粘膜、シロップ、局所、非経口投与、注射、皮下、経口溶液、直腸投与、口腔内投与または経皮投与。
- 請求項4に記載の医薬組成物において、前記医薬組成物は、経口投与によって必要とする患者に投与する有効量の基礎となる病因を治療するために処方されることを特徴とする遅延放出または持続放出、経粘膜、シロップ、局所、非経口投与、注射、皮下、経口溶液、直腸投与、口腔内投与または経皮投与。
- 化合物および化合物および組成物は、てんかんの治療、双極性障害、三叉神経痛、注意欠陥多動性障害(ADHD)、統合失調症、神経因性疼痛、発作、双極性障害、躁病、幻肢症候群のために処方されることを特徴とする請求項5に記載の組成物、複合性局所疼痛症候群、発作性極度の疼痛性障害、神経性筋、間欠性爆発性障害、境界性人格障害、先天性ミオトニーおよび心的外傷後ストレス障害。
- 化合物および化合物および組成物は、てんかんの治療、双極性障害、三叉神経痛、注意欠陥多動性障害(ADHD)、統合失調症、神経因性疼痛、発作、双極性障害、躁病、幻肢症候群のために処方されることを特徴とする請求項6に記載の組成物、複合性局所疼痛症候群、発作性極度の疼痛性障害、神経性筋、間欠性爆発性障害、境界性人格障害、先天性ミオトニーおよび心的外傷後ストレス障害。
- さらに5H−ジベンゾ[b 、 f]をアゼピン−5−カルボキサミド及び10オキソ−10,11−ジヒドロ−5H−ジベンゾ[bからなる群から選択されるカルボキサミド化合物の分子複合体を含む、請求項3に記載の医薬組成物で、f ]アゼピン−5−カルボキサミド、及びR− α−リポ酸、エイコサペンタエン酸及びドコサヘキサエン酸からなる群から選択されるカルボン酸化合物。
- カルボン酸化合物は、 R− α−リポ酸である、請求項9に記載の分子複合体。
- カルボン酸化合物がエイコサペンタエン酸である、請求項9に記載の分子複合体。
- カルボン酸化合物が、ドコサヘキサエン酸である、請求項9に記載の分子複合体。
- カルボキサミド化合物5H−ジベンゾ[b 、 f]をアゼピン−5−カルボキサミドである、請求項9に記載の分子複合体、
- カルボキサミド化合物は、10−オキソ−10,11−ジヒドロ−5H−ジベンゾ[b 、 f]をアゼピン−5−カルボキサミドである、請求項9に記載の分子複合体。
- さらに5H−ジベンゾ[b 、 f]をアゼピン−5−カルボキサミド及び10オキソ−10,11−ジヒドロ−5H−ジベンゾ[bからなる群から選択されるカルボキサミド化合物の分子複合体を含む、請求項4に記載の医薬組成物で、f ]アゼピン−5−カルボキサミド、及びR− α−リポ酸、エイコサペンタエン酸及びドコサヘキサエン酸からなる群から選択されるカルボン酸化合物。
- カルボン酸化合物は、 R− α−リポ酸である、請求項15に記載の分子複合体。
- カルボン酸化合物がエイコサペンタエン酸である、請求項15に記載の分子複合体。
- カルボン酸化合物が、ドコサヘキサエン酸である、請求項15に記載の分子複合体。
- カルボキサミド化合物5H−ジベンゾ[b 、 f]をアゼピン−5−カルボキサミドである、請求項15に記載の分子複合体。
- カルボキサミド化合物は、 10−オキソ−10,11−ジヒドロ−5H−ジベンゾ[b 、 f]をアゼピン−5−カルボキサミドである、請求項15に記載の分子複合体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1782/CHE/2012 | 2012-05-07 | ||
IN1782CH2012 | 2012-05-07 | ||
PCT/IB2013/050711 WO2013167985A1 (en) | 2012-05-07 | 2013-01-28 | Compositions and methods for the treatment of neurological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015519333A true JP2015519333A (ja) | 2015-07-09 |
JP2015519333A5 JP2015519333A5 (ja) | 2015-08-27 |
Family
ID=54193685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015510892A Pending JP2015519333A (ja) | 2012-05-07 | 2013-01-28 | 神経疾患の治療のための組成物および方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9738631B2 (ja) |
EP (1) | EP2847169A4 (ja) |
JP (1) | JP2015519333A (ja) |
CN (1) | CN104350041A (ja) |
AU (1) | AU2013257706A1 (ja) |
CA (1) | CA2872975A1 (ja) |
SG (1) | SG11201407300VA (ja) |
WO (1) | WO2013167985A1 (ja) |
ZA (1) | ZA201408060B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015519334A (ja) * | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 抗血小板薬のプロドラッグ |
JP2015527309A (ja) * | 2012-07-03 | 2015-09-17 | セリックスビオ プライヴェート リミテッド | 中等度から重度の疼痛の治療のための組成物及び方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2976314C (en) * | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN106588773B (zh) * | 2016-11-10 | 2019-09-27 | 北京现代药物代谢研究院 | 一种脑靶向艾司利卡西平酯类前药及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49126689A (ja) * | 1973-03-30 | 1974-12-04 | ||
JPH09110836A (ja) * | 1995-06-30 | 1997-04-28 | Portela & Co Sa | 置換されたジヒドロジベンゾ/b,f/アゼピン、これらの製造方法、幾つかの中枢神経系疾患の治療におけるこれらの使用、及びこれらを含有する薬学的組成物 |
JP2009528278A (ja) * | 2006-02-14 | 2009-08-06 | バイアル−ポルテラ アンド シーエー,エス.エー. | 神経障害性疼痛及び神経障害の治療における5H−ジベンズ/b,f/アゼピン−5−カルボキサミド誘導体の使用 |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2807644A (en) | 1954-08-20 | 1957-09-24 | Parke Davis & Co | Pantethine inhibitors |
DE1205972B (de) | 1963-08-20 | 1965-12-02 | Merck Ag E | Verfahren zur Herstellung eines Liponsaeure-derivates |
US4011342A (en) | 1971-06-02 | 1977-03-08 | Seperic | Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines |
DD101670A1 (ja) * | 1972-02-22 | 1973-11-12 | ||
JPS5677259A (en) | 1979-11-29 | 1981-06-25 | Nippon Chemiphar Co Ltd | N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation |
WO1981002671A1 (en) | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
US4404366A (en) * | 1980-05-06 | 1983-09-13 | Miles Laboratories, Inc. | Beta-galactosyl-umbelliferone-labeled hapten conjugates |
US4412992A (en) | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
US4440763A (en) | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
IT1190727B (it) | 1982-03-10 | 1988-02-24 | Ausonia Farma Srl | Composto ad attivita' analgesica,antiinfiammatoria e mucoregolatrice procedimento per la sua preparazione e relative composizioni farmaceutiche |
FR2528038B2 (fr) | 1982-06-04 | 1985-08-09 | Lafon Labor | Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique |
US4564628A (en) | 1983-01-03 | 1986-01-14 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
US5104887A (en) | 1983-02-04 | 1992-04-14 | University Of Iowa Research Foundation | Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors |
JPS6089474A (ja) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | モルフイナン誘導体,その製造方法,及び該化合物を含有する抗腫瘍剤 |
IL73293A (en) * | 1983-11-04 | 1988-02-29 | Abbott Lab | Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives |
IT1213132B (it) | 1984-02-02 | 1989-12-14 | Yason Srl | Agente antibroncopneumopatico. |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
US4873259A (en) | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
US5120738A (en) | 1989-10-06 | 1992-06-09 | Fujirebio Inc. | Pantothenic acid derivatives |
US5242937A (en) | 1990-03-19 | 1993-09-07 | Research Corporation Technologies, Inc. | Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors |
IT1248702B (it) | 1990-06-06 | 1995-01-26 | Yason Srl | Agente antitussivo e mucoregolatore,sua preparazione e composizioni farmaceutiche |
FR2699077B1 (fr) | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
FR2707637B1 (fr) | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
SE9401727D0 (sv) | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds I |
FR2722199B3 (fr) | 1994-07-11 | 1996-09-06 | Univ Picardie Jules Verne Etab | Derives de l'acide valproique et leurs applications comme medicaments |
US6156777A (en) | 1994-12-15 | 2000-12-05 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
NZ334389A (en) | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
KR20000069075A (ko) | 1996-11-22 | 2000-11-25 | 진 엠. 듀발 | N-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법 |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
GB9710351D0 (en) | 1997-05-20 | 1997-07-16 | Scotia Holdings Plc | Glucosamine fatty acids |
NZ333474A (en) | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
RU2203887C2 (ru) | 1998-02-27 | 2003-05-10 | Санкио Компани, Лимитед | Циклические аминопроизводные, фармацевтическая композиция и способ профилактики заболевания |
JP3761324B2 (ja) | 1998-05-15 | 2006-03-29 | ヤンマー農機株式会社 | 乗用田植機 |
US6846495B2 (en) | 1999-01-11 | 2005-01-25 | The Procter & Gamble Company | Compositions having improved delivery of actives |
ES2305606T3 (es) | 1999-04-06 | 2008-11-01 | Sepracor Inc. | Succinato de o-desmetilvenlafaxina. |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
CA2385990A1 (en) | 1999-09-29 | 2001-04-05 | The Procter & Gamble Company | Compositions having improved stability |
US6429223B1 (en) | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US6602915B2 (en) | 2000-07-27 | 2003-08-05 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
MXPA03003575A (es) | 2000-10-24 | 2003-07-14 | Ajinomoto Kk | Procedimiento para elaborar la forma b del cristal de nateglinida. |
DE10103506A1 (de) | 2001-01-26 | 2002-08-14 | Ingo S Neu | Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
JP2005525293A (ja) | 2001-08-29 | 2005-08-25 | エンドー ファーマシューティカルズ, インコーポレイティド | 鎮痛薬およびその使用方法 |
US7138133B2 (en) | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US20030220344A1 (en) | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
WO2003087038A1 (en) | 2002-04-15 | 2003-10-23 | Novartis Ag | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
JP2005526107A (ja) | 2002-04-16 | 2005-09-02 | 藤沢薬品工業株式会社 | 慢性拒絶反応を予防および/または処置するための医薬 |
US7060725B2 (en) | 2002-05-13 | 2006-06-13 | Janssen Pharmaceutica N.V. | Substituted sulfamate anticonvulsant derivatives |
GB0223224D0 (en) * | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
DK1988397T3 (da) | 2002-12-19 | 2011-12-12 | Scripps Research Inst | Præparater og anvendelser til stabilisering af transthyretin og inhibering af transthyretin-fejlfoldning |
BRPI0407256A (pt) | 2003-02-14 | 2006-01-31 | Pf Medicament | Utilização do enantiÈmero (1s,2r) do milnacipran para a preparação de um medicamento |
UA81657C2 (ru) | 2003-03-04 | 2008-01-25 | Орто-Макнейл Фармасьютикел, Инк. | Способ получения противосудорожных производных топирамата |
GB2401605A (en) * | 2003-05-12 | 2004-11-17 | Portela & Ca Sa | Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof |
NZ601772A (en) | 2003-07-29 | 2012-10-26 | Signature R & D Holdings Llc | Amino Acid Prodrugs |
CN1867322B (zh) | 2003-10-14 | 2014-06-25 | 什诺波特有限公司 | 结晶形式的γ-氨基丁酸类似物 |
US7470435B2 (en) | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
TW200526624A (en) | 2003-11-28 | 2005-08-16 | Sankyo Co | Cyclic aryl derivatives containing with heteroaryl ring |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
CN1248690C (zh) | 2004-03-25 | 2006-04-05 | 华中师范大学 | 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂 |
WO2005116086A2 (en) | 2004-04-07 | 2005-12-08 | The University Of Georgia Research Foundation, Inc. | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
UA88464C2 (ru) | 2004-04-29 | 2009-10-26 | Колдуэлл Гейлер, Инк. | Способ дермального введения метадоновой композиции с обеспечением системного действия |
CN1672678A (zh) | 2004-05-03 | 2005-09-28 | 深圳微芯生物科技有限责任公司 | 预防和治疗前列腺疾病的长链脂肪酸天然活性成分的分离、提取和药用制剂的制备和应用 |
NZ551511A (en) | 2004-06-04 | 2010-09-30 | Xenoport Inc | Levodopa prodrugs, and compositions and uses thereof |
CN100455560C (zh) | 2004-06-09 | 2009-01-28 | 中国人民解放军军事医学科学院放射医学研究所 | 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途 |
EP1863433A4 (en) | 2005-03-18 | 2009-09-09 | Ripped Formulations Ltd | COMPOSITIONS AND METHODS FOR INCREASING METABOLISM, HEAT GENERATION AND / OR MUSCLE EDUCATION |
WO2006120176A2 (en) | 2005-05-11 | 2006-11-16 | Nycomed Gmbh | Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative |
DE102005022276A1 (de) | 2005-05-13 | 2006-11-16 | Ellneuroxx Ltd. | Derivate von Dihydroxyphenylalanin |
US20060270635A1 (en) | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
KR20080013944A (ko) | 2005-05-27 | 2008-02-13 | 다이이찌 산쿄 가부시키가이샤 | 치환 알킬기를 갖는 고리형 아민 유도체 |
WO2006125293A1 (en) | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
EP1940398A1 (de) | 2005-10-18 | 2008-07-09 | Boehringer Ingelheim International GmbH | Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls) |
AU2007208681B2 (en) | 2006-01-27 | 2010-04-08 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
US20070259930A1 (en) | 2006-04-10 | 2007-11-08 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
EP1870395A1 (en) | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
US7943666B2 (en) | 2006-07-24 | 2011-05-17 | Trinity Laboratories, Inc. | Esters of capsaicin for treating pain |
US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CN100573950C (zh) | 2006-12-14 | 2009-12-23 | 财团法人工业技术研究院 | 相变存储装置及其制造方法 |
EP2101766B1 (en) | 2006-12-14 | 2016-09-21 | Knopp Biosciences LLC | Compositions and methods of using (r)-pramipexole |
AU2007338631A1 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
WO2008089008A2 (en) | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin prodrugs |
ES2319024B1 (es) | 2007-02-13 | 2009-12-11 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina. |
JP2010521496A (ja) | 2007-03-14 | 2010-06-24 | ノップ ニューロサイエンシーズ、インク. | キラル精製置換ベンゾチアゾールジアミンの合成 |
DK2522667T3 (da) | 2007-05-01 | 2014-11-03 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
EP1997493A1 (en) | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand |
EP2190853A4 (en) | 2007-06-22 | 2011-08-31 | Gluconova Llc | HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID |
US20090075942A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fosamprenavir |
CN101390854A (zh) | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | 一种含有利鲁唑的药用组合物 |
WO2009056791A1 (en) | 2007-11-02 | 2009-05-07 | Pliva Hrvatska D.O.O. | Processes for preparing pharmaceutical compounds |
WO2009061934A1 (en) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
CN101186583B (zh) | 2007-12-20 | 2011-05-11 | 吉林大学 | 2-(2-(2,6-二氯苯基氨基)苯基)醋酸甲酯及其合成方法及其应用 |
US20100081713A1 (en) | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
CN102512405B (zh) | 2008-04-30 | 2015-08-05 | 上海医药工业研究院 | 一类长链脂肪酸衍生物或含其的植物提取物在制备抑制芳香化酶活性的药物中的应用 |
KR100990949B1 (ko) | 2008-06-09 | 2010-10-29 | 엔자이텍 주식회사 | 클로피도그렐 및 그의 유도체의 제조방법 |
CN104000808A (zh) | 2008-07-08 | 2014-08-27 | 凯特贝希制药公司 | 脂肪酸乙酰化的水杨酸酯及其用途 |
CA2806444C (en) | 2008-08-19 | 2016-02-23 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate |
RU2540465C2 (ru) | 2008-08-22 | 2015-02-10 | Вокхардт Рисерч Сентер | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения |
WO2010073124A2 (en) | 2008-12-26 | 2010-07-01 | Actavis Group Ptc Ehf | Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof |
BRPI0901298A2 (pt) | 2009-04-06 | 2011-01-04 | Ems Sa | derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias |
CN104042617A (zh) | 2009-04-29 | 2014-09-17 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
WO2010147666A1 (en) | 2009-06-19 | 2010-12-23 | Memorial Sloan-Kettering Cancer Center | Compounds useful as carbonic anhydrase modulators and uses thereof |
EP2464626A4 (en) | 2009-08-10 | 2015-12-16 | Bhi Ltd Partnership | PROCESSES, COMPOUNDS AND COMPOSITIONS FOR THE EXPORTS OF 1,3-PROPANE-SULFONIC ACID |
CN102002053A (zh) | 2009-09-02 | 2011-04-06 | 陕西合成药业有限公司 | 用于治疗的四氢噻吩并吡啶衍生物 |
CN101717392A (zh) | 2009-10-09 | 2010-06-02 | 苏州凯达生物医药技术有限公司 | 一种制备罗替戈汀及其衍生物的方法 |
CN102050815B (zh) | 2009-11-06 | 2014-04-02 | 北京美倍他药物研究有限公司 | 作为前药的达比加群的酯衍生物 |
CN101724934B (zh) | 2009-11-10 | 2012-07-04 | 东华大学 | 一种用于治疗皮肤炎症和疼痛的药用纤维及其制备和应用 |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
ES2637266T3 (es) | 2010-01-08 | 2017-10-11 | Catabasis Pharmaceuticals, Inc. | Derivados fumarato de ácido graso y sus usos |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
RU2436772C2 (ru) | 2010-01-28 | 2011-12-20 | Закрытое акционерное общество "НПК ЭХО" | 4[(4'-никотиноиламино)бутироиламино]бутановая кислота, проявляющая ноотропную активность, и способ ее получения |
WO2011106688A1 (en) | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
AU2011263423B2 (en) | 2010-06-08 | 2016-10-20 | Krisani Biosciences (P) Ltd | Cysteamine derivatives and their use in the treatment of NASH |
HUE038399T2 (hu) | 2010-07-12 | 2018-10-29 | Sanofi Aventis Deutschland | Brómhexint tartalmazó vizes kompozíció |
AR082499A1 (es) | 2010-08-23 | 2012-12-12 | Gruenenthal Gmbh | Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
CN101921245B (zh) | 2010-08-30 | 2012-04-18 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途 |
EP2632451B1 (en) | 2010-10-29 | 2017-10-18 | Algiax Pharmaceuticals GmbH | Use of malononitrilamides in neuropathic pain |
EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
WO2013008182A1 (en) | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
CN102336767A (zh) | 2011-07-11 | 2012-02-01 | 华东理工大学 | 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法 |
WO2013017974A1 (en) | 2011-07-30 | 2013-02-07 | Mahesh Kandula | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
WO2013024376A1 (en) | 2011-08-16 | 2013-02-21 | Mahesh Kandula | Compositions and methods for the treatment of atherothrombosis |
WO2013027150A1 (en) | 2011-08-21 | 2013-02-28 | Mahesh Kandula | Compositions and methods for the treatment of parkinson's disease |
CN102633799B (zh) | 2012-04-10 | 2014-06-25 | 凯莱英医药集团(天津)股份有限公司 | 一种从消旋体中间体拆分路线合成二盐酸沙丙蝶呤的方法 |
WO2013168022A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treating atherothrombosis |
WO2013167988A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of cough |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
SG11201407411SA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
-
2013
- 2013-01-28 CA CA2872975A patent/CA2872975A1/en not_active Abandoned
- 2013-01-28 AU AU2013257706A patent/AU2013257706A1/en not_active Abandoned
- 2013-01-28 WO PCT/IB2013/050711 patent/WO2013167985A1/en active Application Filing
- 2013-01-28 CN CN201380030626.0A patent/CN104350041A/zh active Pending
- 2013-01-28 JP JP2015510892A patent/JP2015519333A/ja active Pending
- 2013-01-28 SG SG11201407300VA patent/SG11201407300VA/en unknown
- 2013-01-28 US US14/533,113 patent/US9738631B2/en active Active
- 2013-01-28 EP EP13787695.9A patent/EP2847169A4/en not_active Withdrawn
-
2014
- 2014-11-04 ZA ZA2014/08060A patent/ZA201408060B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49126689A (ja) * | 1973-03-30 | 1974-12-04 | ||
JPH09110836A (ja) * | 1995-06-30 | 1997-04-28 | Portela & Co Sa | 置換されたジヒドロジベンゾ/b,f/アゼピン、これらの製造方法、幾つかの中枢神経系疾患の治療におけるこれらの使用、及びこれらを含有する薬学的組成物 |
JP2009528278A (ja) * | 2006-02-14 | 2009-08-06 | バイアル−ポルテラ アンド シーエー,エス.エー. | 神経障害性疼痛及び神経障害の治療における5H−ジベンズ/b,f/アゼピン−5−カルボキサミド誘導体の使用 |
Non-Patent Citations (2)
Title |
---|
JPN6016030754; Journal of Medicinal Chemistry 42(14), 1999, pp.2582-2587 * |
JPN6016030755; Drugs of the Future 34(3), 2009, pp.189-195 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015519334A (ja) * | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 抗血小板薬のプロドラッグ |
JP2015527309A (ja) * | 2012-07-03 | 2015-09-17 | セリックスビオ プライヴェート リミテッド | 中等度から重度の疼痛の治療のための組成物及び方法 |
Also Published As
Publication number | Publication date |
---|---|
US20160122332A1 (en) | 2016-05-05 |
ZA201408060B (en) | 2016-03-30 |
AU2013257706A1 (en) | 2014-11-27 |
CN104350041A (zh) | 2015-02-11 |
SG11201407300VA (en) | 2014-12-30 |
EP2847169A1 (en) | 2015-03-18 |
CA2872975A1 (en) | 2013-11-14 |
US9738631B2 (en) | 2017-08-22 |
WO2013167985A1 (en) | 2013-11-14 |
EP2847169A4 (en) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9765020B2 (en) | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis | |
US20150133533A1 (en) | Compositions and methods for the treatment of cough | |
US9492409B2 (en) | Compositions and methods for the treatment of local pain | |
WO2014115098A1 (en) | Compositions and methods for the treatment of neurological diseases and inflammation | |
JP2015519333A (ja) | 神経疾患の治療のための組成物および方法 | |
EP3242869A1 (en) | Compositions and methods for the treatment of inflammation and pain | |
WO2014091384A2 (en) | Compositions and methods for the treatment of mucositis | |
JP2015519333A5 (ja) | ||
US9096537B1 (en) | Compositions and methods for the treatment of mucositis | |
AU2013257710B2 (en) | Compositions and methods for the treatment of neurological disorders | |
US10208014B2 (en) | Compositions and methods for the treatment of neurological disorders | |
JP2015526385A (ja) | てんかんの治療のための組成物及び方法 | |
US9346742B2 (en) | Compositions and methods for the treatment of fibromyalgia pain | |
WO2014057439A2 (en) | Compositions and methods for the treatment of neurological diseases and its associated complications | |
US9242939B2 (en) | Compositions and methods for the treatment of respiratory disorders | |
EP3256459A1 (en) | Compositions and methods for the treatment of mucositis | |
US9227974B2 (en) | Compositions and methods for the treatment of respiratory disorders | |
WO2015028957A2 (en) | Compounds and methods for the treatment of respiratory diseases | |
US9399634B2 (en) | Compositions and methods for the treatment of depression | |
US9339484B2 (en) | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia | |
US20150087674A1 (en) | Compositions and methods for the treatment of severe pain | |
US20150141384A1 (en) | Compositions and methods for the treatment of neurological degenerative disorders | |
US20150087697A1 (en) | Compositions and methods for the treatment of muscle pain | |
US20170327482A1 (en) | Compositions and methods for the treatment of mucositis | |
WO2016046669A2 (en) | Compositions and methods for the treatment of depression and neurological diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150601 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160413 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160804 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160816 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170314 |